Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells-Reference-Cited by-同舟云学术

Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells

Published:2016-09-19 Issue:11 Volume:5 Page:e1232220
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Weng Jinsheng,Baio Flavio Egidio,Moriarty Kelsey E.,Torikai Hiroki,Wang Hua,Liu Zhiqiang,Maiti Sourindra N.,Gwak Dongho,Popescu Michael S.,Cha Soung-Chul,Cooper Laurence J. N.,Neelapu Sattva S.,Kwak Larry W.

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1232220

Reference50 articles.

1. Relapsed and refractory aggressive NHL: Time for a change

2. Adoptive cell transfer: a clinical path to effective cancer immunotherapy

3. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy

4. Helping the CD8+ T-cell response

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lymphoma Vaccines: Background and Perspectives;Cancer Immunotherapy;2024

2. New insights into B cells as antigen presenting cells;Current Opinion in Immunology;2021-06

3. Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma;Cancer Immunology, Immunotherapy;2020-04-22

4. Personal tumor antigens in blood malignancies: genomics-directed identification and targeting;Journal of Clinical Investigation;2020-01-27

5. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial;Clinical Cancer Research;2019-06-06